Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial
Russell, Stephen, Bennett, Jean, Wellman, Jennifer A, Chung, Daniel C, Yu, Zi-Fan, Tillman, Amy, Wittes, Janet, Pappas, Julie, Elci, Okan, McCague, Sarah, Cross, Dominique, Marshall, Kathleen A, Walshire, Jean, Kehoe, Taylor L, Reichert, Hannah, Davis, Maria, Raffini, Leslie, George, Lindsey A, Hudson, F Parker, Dingfield, Laura, Zhu, Xiaosong, Haller, Julia A, Sohn, Elliott H, Mahajan, Vinit B, Pfeifer, Wanda, Weckmann, Michelle, Johnson, Chris, Gewaily, Dina, Drack, Arlene, Stone, Edwin, Wachtel, Katie, Simonelli, Francesca, Leroy, Bart P, Wright, J Fraser, High, Katherine A, Maguire, Albert M
Published in The Lancet (British edition) (26.08.2017)
Published in The Lancet (British edition) (26.08.2017)
Get full text
Journal Article